Rabbit Polyclonal IL24 Antibody

+ +

•  

   
     All lanes : Anti-IL24 Antibody at 1:2000 dilution Lane 1: Hela whole cell lysates Lane 2: Jurkat whole cell lysates Lane 3: K562 whole cell lysates Lane 4: A431 whole cell lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution Predicted band size : 24 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Overlay histogram showing U-2 OS cells stained with P33065 (green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P33065,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit lgG (H+L) (1583138) at 1/400 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     P33065 staining IL24 in human melanoma sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

The IL-24 antibody targets interleukin-24 (IL-24), a cytokine belonging to the IL-10 family, initially identified for its role in immune regulation and tumor suppression. IL-24 is produced by immune cells, including macrophages and Th2 cells, and exhibits dual functionality: it promotes pro-inflammatory responses while selectively inducing apoptosis in cancer cells without harming normal tissues. Its antitumor activity involves mechanisms such as cell cycle arrest, inhibition of angiogenesis, and activation of stress pathways via binding to IL-20R1/IL-20R2 or IL-22R1/IL-20R2 receptor complexes.

IL-24 antibodies are essential tools for studying IL-24's expression, signaling, and therapeutic potential. Monoclonal antibodies (mAbs) against IL-24 are used in immunoassays (ELISA, Western blot, immunohistochemistry) to quantify protein levels in research models or clinical samples. In therapeutic contexts, neutralizing IL-24 antibodies may help mitigate inflammatory diseases, while agonist antibodies could enhance IL-24's antitumor effects. Preclinical studies highlight IL-24's promise in treating melanoma, breast, and lung cancers, often in combination with gene therapy or checkpoint inhibitors. However, challenges remain in optimizing delivery and minimizing off-target effects. Research continues to explore IL-24 antibodies as both diagnostic biomarkers and targeted therapies for cancer and autoimmune disorders.